Celcuity Announced Overall Survival Data From Two Patient Cohorts Evaluated In A Phase 1B Trial With Gedatolisib, A PI3K/mTORC1/2 Inhibitor, In Combination With Palbociclib And Either Letrozole Or Fulvestrant, In Patients With HR+, HER2-advanced Or...
BofA Securities Maintains Celsius Holdings(CELH.US) With Sell Rating, Maintains Target Price $26
Analysts Offer Insights on Consumer Goods Companies: Constellation Brands (STZ) and Celsius Holdings (CELH)
Shareholder Alert for Celsius Holdings, Inc. (NASDAQ:CELH)
Celsius Holdings Options Spot-On: On December 10th, 165.83K Contracts Were Traded, With 608.83K Open Interest
(CELH) - Analyzing Celsius Holdings's Short Interest
